Sherlock Biosciences

Key People

• Feng Zhang - Co-Founder & Chair of Advisory Board
• Jim Collins - Co-Founder & Director
• Todd Golub - Co-Founder
• Jonathan Gootenberg - Co-Founder
• Paul M. Meister - Board Member
• Michael Rubin - Board Member

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team comprises renowned scientific pioneers and diagnostic veterans with extensive experience in CRISPR and synthetic biology.

Sherlock Biosciences was founded by experts from the Broad Institute and Harvard Universitys Wyss Institute, bringing together leaders in CRISPR and synthetic biology. This strong foundation enhances the company's capability to develop cutting-edge diagnostic solutions.

Clinical Need

Aspect: Very Strong
Summary: The company addresses a critical need for rapid, accurate, and affordable diagnostic tests accessible at the point-of-need.

With the increasing prevalence of infectious diseases and the necessity for timely diagnosis, Sherlock's focus on point-of-care diagnostics fulfills a substantial market demand, potentially reducing disease transmission and improving patient outcomes.

Competition

Aspect: Somewhat crowded
Summary: The molecular diagnostics market is competitive, with several players developing rapid diagnostic tests.

While the market has multiple entrants, Sherlock's proprietary platforms like SHERLOCK and INSPECTR offer unique advantages. However, continuous innovation and strategic collaborations are essential to maintain a competitive edge.

Technical Challenge

Aspect: Predictable
Summary: The development of CRISPR-based diagnostics is complex but follows established scientific principles.

Leveraging CRISPR and synthetic biology, Sherlock's platforms are built on well-understood mechanisms, reducing unforeseen technical hurdles. The team's proficiency further ensures the successful translation of these technologies into viable products.

Patent

Aspect: Very Strong
Summary: The company holds over 65 patents, providing a robust intellectual property portfolio.

A substantial patent portfolio safeguards Sherlock's innovations, deterring competitors and facilitating strategic partnerships or licensing opportunities, thereby strengthening its market presence.

Financing

Aspect: Well-funded
Summary: Raised $111 million to date, indicating strong investor confidence.

The significant capital raised enables Sherlock to advance its product pipeline, conduct necessary clinical trials, and scale operations, positioning the company for successful market entry and growth.

Regulatory

Aspect: Running FIH
Summary: The CT/NG self-test is in clinical studies, with FDA submission expected by end of 2025.

Timely FDA submission and approval are critical for market entry. Sherlock's adherence to regulatory timelines reflects effective management and increases the likelihood of successful product launch.

Opportunity Rollup

Odds of Success

4.1

Peak Market Share

5.05

Segment CAGR

7.1%

Market Segment

In Vitro Diagnostics

Market Sub Segment

Molecular Diagnostics

Key Takeaway

Sherlock Biosciences, with its strong team and innovative technology, is well-positioned to capitalize on the growing demand for rapid molecular diagnostics, despite facing a competitive landscape.